Business Context and Reporting Period
This Form 8-K filing by Indaptus Therapeutics, Inc. (INDP) reports on events occurring through June 30, 2025, with the report dated July 1, 2025. The Company, a Delaware corporation listed on the Nasdaq Capital Market, announced the completion of a private placement of convertible promissory notes and warrants.
Key Financial Metrics and Capital Structure
- Total Capital Raised: Approximately $5.7 million in aggregate principal amount of convertible promissory notes (Notes).
- Transaction Structure: The offering consisted of two closings: $2.3 million on June 12, 2025, and $3.4 million on June 30, 2025.
- Interest Rate: Notes bear interest at 6% per annum.
- Maturity Date: July 28, 2026.
- Placement Agent Fees: 12.0% of gross proceeds in cash plus a $25,000 non-accountable expense.
- Placement Agent Warrants: Warrants to purchase 12.0% of the Conversion Shares issuable upon conversion of the Notes.
Material Changes and Transaction Details
The primary material change is the entry into definitive agreements for the private placement described above. Key terms include:
- Conversion Terms: Notes convert into Common Stock at 80% of the average Nasdaq closing price for the five trading days preceding the Conversion Date, subject to a maximum conversion price of $11.20.
- Conversion Timing: Conversion occurs on the earlier of 30 days following the effectiveness of a reverse split (July 27, 2025) or the one-year anniversary of issuance.
- Beneficial Ownership Limits: If conversion would result in a holder owning more than 4.99% or 9.99% of outstanding shares, the holder receives Pre-Funded Warrants with an exercise price of $0.01 instead of shares.
- Warrant Terms: Purchasers receive warrants equal to 200% of the Conversion Shares. These are exercisable at the Conversion Price and expire five years after the later of the Conversion Date or stockholder approval.
- Stockholder Approval: A special stockholder meeting is scheduled for July 25, 2025, to approve the issuance of shares upon conversion.
Use of Proceeds and Outlook
Management intends to use the net proceeds from the offering for:
- Research and development activities.
- Funding a Phase 1b/2 clinical trial.
- Working capital and general corporate purposes.
- Verify the outcome of the special stockholder meeting scheduled for July 25, 2025, regarding approval of the share issuance.
- Confirm the final conversion price once the Conversion Date is determined, noting the $11.20 cap.
- Monitor the filing of the registration statement for resale of securities within 30 days of the Conversion Date.
- Review the impact of the 200% warrant overhang on future share count and dilution.
- Check for updates on the Phase 1b/2 clinical trial funding status and timeline.
Risks and Contingencies: The issuance is subject to Nasdaq Listing Rule 5635(d) limitations on the number of shares issuable. The Company has agreed to file a registration statement within 30 days of the Conversion Date for the resale of Conversion Shares and Warrant Shares.